Chemistry: molecular biology and microbiology – Treatment of micro-organisms or enzymes with electrical or... – Modification of viruses
Patent
1994-07-21
1997-07-01
Fleisher, Mindy
Chemistry: molecular biology and microbiology
Treatment of micro-organisms or enzymes with electrical or...
Modification of viruses
435 697, 4353201, 424 932, 530350, 536 234, C12N 1586, C12N 1548, C07K 1415, A61K 4800
Patent
active
056437706
ABSTRACT:
Modified retroviral vector particles and modified retroviral producer cells producing such particles are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The modifications involve genetic alterations to effect the expression by these cells and particles of complement inhibitor activity. The genetic alterations involve the introduction of nucleic acid expression constructs directing the expression of retroviral SU(gp70)/complement inhibitor chimeric proteins into cells from which the producer cells are derived.
REFERENCES:
Takeuchi et al., J. Virol. 68(12):8001-8007 (1994).
"Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," Orkin and Motulsky, Co-chairs, Dec. 7, 1995.
Kennedy et al., Transplantation 57(10):1494-1501 (1994).
Hayashi et al., Transplantation Proceedings 26(3):1243-1244 (1994).
Marschang et al., European Journal of Immunology 25:285-290 (1995).
Mulligan, Science 260:926-932 (1993).
Albrecht and Fleckenstein, "New member of the multigene family of complement control proteins in herpesvirus saimiri" J. Virol, 66:3937-3940, 1992.
Albrecht et al., "Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59" Virology, 190:527-530, 1992.
Bartholomew et al., "Lysis of oncornaviruses by human serum" J. Exp Med, 147:844-853, 1978.
Bartholomew and Esser, "Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes" Biochemistry, 19:2847-2853, 1980.
Cooper et al., "Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway" J. Exp Med, 144:970-984, 1976.
Culver et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors" Science, 256:1550-1552, 1992.
Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence" Proc Natl Acad Sci, USA, 89:628-632, 1992.
McNearney et al., "Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity" J Exp Med, 166:1525-1535, 1987.
Ram et al., "Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors" J Neurosurg, 79:400-407, 1993.
Rother et al., "Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri" J. Virol, 68:730-737, 1994.
Welsh et al., "Human serum lyses RNA tumur viruses" Nature, 257:612-614, 1975.
Welsh et al., "Inactivation and lysis of oncornaviruses by human serum" Virology, 74:432-440, 1976.
Mason James M.
Squinto Stephen P.
Alexion Pharmaceuticals, Inc.
Fidel Seth A.
Fleisher Mindy
Klee Maurice M.
Railey II Johnny F.
LandOfFree
Retroviral vector particles expressing complement inhibitor acti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral vector particles expressing complement inhibitor acti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vector particles expressing complement inhibitor acti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-596074